CG Oncology Extends Cash Runway to 2029, Expedites Key Phase 3 Data Readout
Summary
CG Oncology reported its 2025 year-end financial results, highlighting a robust cash position of $903.0 million as of February 26, 2026. This includes approximately $286.4 million raised through its at-the-market (ATM) facility in Q4 2025 and January 2026, following the ATM expansion announced in January. The company now projects its cash, cash equivalents, and marketable securities will fund operations into the first half of 2029, significantly de-risking its financial outlook. Furthermore, CG Oncology announced an expedited timeline for topline Phase 3 data from its PIVOT-006 clinical trial in intermediate-risk NMIBC to the first half of 2026, alongside first results from the CORE-008 Cohort CX Phase 2 trial in the same period and a BLA submission in 2026. These updates provide strong financial stability and multiple near-term clinical catalysts for the company.
At the time of this announcement, CGON was trading at $57.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $14.80 to $60.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.